Philips Launches HyperVue Integrated for US Coronary Imaging

Philips has announced US commercial availability of HyperVue Integrated, a fixed configuration that keeps coronary imaging and physiology tools connected inside a dedicated interventional suite. The launch centres on how clinicians access those tools during procedures, rather than introducing a new claim that installing the system improves patient outcomes. Philips News & Insights report.

A permanent installation replaces repeated setup

In its announcement, Philips contrasts the integrated configuration with its mobile HyperVue system. The mobile equipment must be moved into the procedure room, powered and connected for each case. HyperVue Integrated remains installed in a dedicated room, making the imaging capability available without those repeated preparation steps.

The company says eliminating movement and connection tasks is intended to reduce setup work and improve everyday access. That is the operational proposition behind this launch. It should be read as the manufacturer's description of the system's design, not as independent evidence of shorter procedures or better clinical results.

Related coverage: Philips Brings CT Planning Into Azurion With UniGuide 3D.

Imaging and physiology share the platform

HyperVue combines DeepOCT+NIRS intravascular imaging with X1-FFR physiology assessment. Philips describes X1-FFR as an AI-powered, angiography-derived platform that provides drug-free coronary physiology information. Its announcement presents the tools as complementary ways to support coronary disease assessment and treatment decisions within the interventional suite.

Philips says X1-FFR uses a single angiographic view to provide an FFR value. The company identifies it as FDA-cleared and cites supporting material in the announcement. Those statements concern the specified system and its regulatory status; they should not be expanded into a general claim about AI replacing clinical judgement.

Related coverage: MIT Magnetic Beads Track Muscle Motion for Prosthetic Control.

Bedside controls are part of the configuration

A table-mounted touchscreen allows the system to be controlled at the bedside from within the sterile field, according to Philips. The integrated configuration also includes controller updates intended to simplify setup and the user experience. Continuous connectivity covers both DeepOCT+NIRS imaging and X1-FFR.

For a purchasing team, our recommendation is to evaluate the installation as a workflow decision as well as an equipment decision. Map where staff currently prepare imaging equipment, when clinicians need access and how the proposed fixed configuration would fit the room. Those are assessment questions, not promised savings.

Related coverage: MIT Combines Ultrasound and Local Infusion in a Brain-delivery Implant.

The launch sits within a wider coronary portfolio

Philips is presenting HyperVue Integrated alongside IntraSight Plus at TCT in San Diego. Its announcement describes IntraSight Plus as a US-available interventional guidance platform combining IVUS, iFR/FFR physiology, co-registration, tri-registration and real-time device visualisation. The products form part of the company's broader coronary guidance offering.

The company frames that portfolio around assessing coronary disease, planning and guiding treatment, and checking procedural results. Different imaging and physiology tools are presented as options for different patients and lesions. The release does not make those distinct platforms interchangeable, and readers should retain their individual product descriptions.

Related coverage: Johnson & Johnson Details Solid Tumour Research Programme for ESMO.

What This Means for Practitioners

Our assessment is that the immediate news is US availability of a permanently connected configuration. Hospitals considering it should request the applicable product documentation, confirm compatibility with their existing room and establish training requirements before interpreting the launch as a change in their own clinical practice.

Separate the manufacturer's workflow objectives from locally measured results. A useful evaluation would examine preparation steps and access to information under the hospital's own operating conditions. Claims about patient outcomes, staffing reductions or financial returns would need their own evidence; they do not follow automatically from this availability announcement.